rs386833874
Variant summary
Our verdict is Pathogenic. Variant got 16 ACMG points: 16P and 0B. PM1PM2PP3_StrongPP5_Very_Strong
The NM_004646.4(NPHS1):c.1219C>T(p.Arg407Trp) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000124 in 1,613,962 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Likely pathogenic (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. R407Q) has been classified as Likely benign.
Frequency
Consequence
NM_004646.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 16 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | UniProt |
---|---|---|---|---|---|---|---|
NPHS1 | NM_004646.4 | c.1219C>T | p.Arg407Trp | missense_variant | 10/29 | ENST00000378910.10 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|
NPHS1 | ENST00000378910.10 | c.1219C>T | p.Arg407Trp | missense_variant | 10/29 | 1 | NM_004646.4 | P2 | |
NPHS1 | ENST00000353632.6 | c.1219C>T | p.Arg407Trp | missense_variant | 10/28 | 5 | A2 | ||
NPHS1 | ENST00000592132.1 | n.226C>T | non_coding_transcript_exon_variant | 3/4 | 3 |
Frequencies
GnomAD3 genomes AF: 0.0000197 AC: 3AN: 152088Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.0000199 AC: 5AN: 251390Hom.: 0 AF XY: 0.0000147 AC XY: 2AN XY: 135872
GnomAD4 exome AF: 0.0000116 AC: 17AN: 1461874Hom.: 0 Cov.: 32 AF XY: 0.0000165 AC XY: 12AN XY: 727236
GnomAD4 genome AF: 0.0000197 AC: 3AN: 152088Hom.: 0 Cov.: 32 AF XY: 0.0000269 AC XY: 2AN XY: 74294
ClinVar
Submissions by phenotype
Finnish congenital nephrotic syndrome Pathogenic:8
Pathogenic, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Oct 22, 2021 | Variant summary: NPHS1 c.1219C>T (p.Arg407Trp) results in a non-conservative amino acid change located in the Immunoglobulin-like domain of the encoded protein sequence. Three of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 2e-05 in 251390 control chromosomes. c.1219C>T has been reported in the literature in multiple individuals affected with Nephrotic Syndrome, Type 1 in homozygous or compound heterozygous states (e.g. Schoeb_2010, Sadowski_2015, Dufek_2019, Sinha_2020). These data indicate that the variant is very likely to be associated with disease. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. Two clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation. Both laboratories classified the variant as likely pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic. - |
Likely pathogenic, criteria provided, single submitter | clinical testing | Johns Hopkins Genomics, Johns Hopkins University | Apr 29, 2022 | NPHS1 c.1219C>T has been identified in the homozygous and compound heterozygous state in multiple individuals with nephrotic syndrome, type 1. This variant (rs386833874) is rare (<0.1%) in a large population dataset (gnomAD:6/282766 total alleles; 0.002122%; no homozygotes) and has been reported in ClinVar (Variation ID: 56430). Three bioinformatic tools queried predict that this substitution would be damaging and the arginine residue at this position is evolutionarily conserved across most mammalian species assessed. We consider NPHS1 c.1219C>T to be likely pathogenic. - |
Likely pathogenic, criteria provided, single submitter | clinical testing | Baylor Genetics | Feb 25, 2024 | - - |
Likely pathogenic, no assertion criteria provided | literature only | Juha Muilu Group; Institute for Molecular Medicine Finland (FIMM) | - | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Vasylyeva lab, Texas Tech University Health Sciences Center | Oct 22, 2021 | - - |
Likely pathogenic, criteria provided, single submitter | clinical testing | Counsyl | Nov 30, 2017 | - - |
Likely pathogenic, no assertion criteria provided | clinical testing | Natera, Inc. | Sep 10, 2020 | - - |
Likely pathogenic, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | Aug 31, 2021 | - - |
not provided Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Invitae | Nov 13, 2023 | This sequence change replaces arginine, which is basic and polar, with tryptophan, which is neutral and slightly polar, at codon 407 of the NPHS1 protein (p.Arg407Trp). This variant is present in population databases (rs386833874, gnomAD 0.01%). This missense change has been observed in individual(s) with NPHS1-related conditions (PMID: 20172850, 25349199, 33980730). In at least one individual the data is consistent with being in trans (on the opposite chromosome) from a pathogenic variant. ClinVar contains an entry for this variant (Variation ID: 56430). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) has been performed at Invitae for this missense variant, however the output from this modeling did not meet the statistical confidence thresholds required to predict the impact of this variant on NPHS1 protein function. For these reasons, this variant has been classified as Pathogenic. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at